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Background & aims: Ageing increases risk of respiratory infections and impairs the response to inﬂuenza
vaccination. Pre- and pro-biotics offer an opportunity to modulate anti-viral defenses and the response
to vaccination via alteration of the gut microbiota. This study investigated the effect of a novel probiotic,
Biﬁdobacterium longum bv. infantis CCUG 52486, combined with a prebiotic, gluco-oligosaccharide, on the
B and T cell response to seasonal inﬂuenza vaccination in young and older subjects .
Methods: In a double-blind, randomized controlled trial, 58 young (18e35 y) and 54 older (60e85 y)
subjects were supplemented with the synbiotic for 8 weeks. At 4 weeks they were administered with a
seasonal inﬂuenza vaccine. B and T cell phenotype and responsiveness to in vitro re-stimulation with the
vaccine were assessed at baseline, 4, 6 and 8 weeks.
Results: B and T cell proﬁles differed markedly between young and older subjects. Vaccination increased
numbers of memory, IgAþmemory, IgGþmemory and total IgGþ B cells in young subjects, but failed to do
so in older subjects and did not signiﬁcantly alter T cell subsets. Seroconversion to the H1N1 subunit in
the older subjects was associated with higher post-vaccination numbers of plasma B cells, but sero-
conversion was less consistently associated with T cell phenotype. B and T cell subsets from both young
and older subjects demonstrated a strong antigen-speciﬁc recall challenge, and although not inﬂuenced
by age, responsiveness to the recall challenge was associated with seroconversion. In older subjects, CMV
seropositivity was associated with a signiﬁcantly lower recall response to the vaccine, but the synbiotic
did not affect the responsiveness of B or T cells to re-stimulation with inﬂuenza vaccine.
Conclusions: Antigen-speciﬁc B and T cell activation following an in vitro recall challenge with the
inﬂuenza vaccine was inﬂuenced by CMV seropositivity, but not by a synbiotic.
Registered under ClinicalTrials.gov Identiﬁer no. NCT01066377.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Immunosenescence reduces protection against infections and
leads to poor responses to vaccination in older individuals [1]; as a
result, inﬂuenza is a major cause of mortality in older adults [2,3].ale; CMV, cytomegalovirus;
lls; URTI, upper respiratory
).
r Ltd. This is an open access articlePoor vaccine efﬁcacy against inﬂuenza in older individuals is not
just a result of impaired antibody production, although this may be
a contributing factor. Helper T cells play a vital role in the genera-
tion of vaccine-speciﬁc antibody production and viral clearance
depends on cytotoxic T cells [4]. In fact, cellular immune function
may even be better correlated with vaccine protection than the
antibody response to inﬂuenza vaccination [5]. Repeated antigenic
stimulation, activation and differentiation of T cells during ageing
causes progressive loss of CD28 and shrinkage of the naïve and
early memory cytotoxic T cell compartments [6,7], altering both the
quantity and quality of antibodies indirectly [8,9]. Therefore,under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mediated immunity with ageing is critical for developing strate-
gies to protect against infection and maintain or enhance the
response to vaccination.
Previous studies investigating the effects of probiotics on the
response to vaccination have mainly focused on antibody produc-
tion. While some studies have reported a modest effect of pro-
biotics on the antibody response to vaccination in adults, trials in
older subjects are largely inconsistent and data are limited [10]. The
strain Biﬁdobacterium longum bv. infantis CCUG 52486 was origi-
nally isolated from a cohort of very healthy elderly subjects (in-
dependent life-style, free of chronic disease, and aged 90 years or
over) in Italy as part of the CROWNALIFE EU FP5 project [11]. It has
been demonstrated to have particular ecological ﬁtness and anti-
pathogenic effects in vitro, and it has immunomodulatory effects
which are strongly inﬂuenced by the age of the host [12].
Furthermore, this strain has been fully genome sequenced so that
genetic traits can potentially be related to biological effects. We
recently reported that although a pre- and probiotic combination
failed to reverse a marked impairment of the antibody response to
inﬂuenza vaccination in older subjects, it did tend to improve
production of vaccine-speciﬁc IgM and IgG in young subjects, but
not older subjects, suggesting an age-dependent response to the
intervention [13]. However, immunological characterization
revealed that the older subjects randomized to the synbiotic had a
signiﬁcantly higher number of senescent (CD28CD57þ) helper T
cells at baseline compared with those randomized to the placebo.
They also had signiﬁcantly greater tendency for seropositivity to
cytomegalovirus (CMV) and higher plasma levels of anti-CMV IgG,
which are associated with replicative senescence of T cells [13].
Moreover, higher numbers of CD28CD57þ helper T cells were
associated with failure to seroconvert to the Brisbane subunit of the
vaccine, strongly suggesting that the subjects randomized to the
synbiotic were already at a signiﬁcant disadvantage in terms of
likely ability to respond to the vaccine compared with those ran-
domized to the placebo [13].
In this study, we examine the effects of the synbiotic on antigen-
speciﬁc B and T cell activation following an in vitro vaccine recall
challenge. This is important because previous studies have focussed
almost entirely on antibody responses to vaccination and there is
no information on the effects of pre- or pro-biotics on B and T cell
recall responses to vaccination.
2. Methods
2.1. Ethics and trial registration
The study protocol was reviewed and approved by the Univer-
sity of Reading Research Ethics Committee (project number: 10/09)
and the National Health Service (NHS) Research Ethics Committee
forWales (10/MRE09/5). The trial was registeredwith ClinicalTrials.
gov (Identiﬁer: NCT01066377) and conducted according to the
guidelines laid down in the Declaration of Helsinki.
2.2. Participants
Prior to the inﬂuenza season of 2010e2011, young (18e35 y) and
older (60e85 y) healthy adults were recruited from the population
in and around Reading (UK) through newspaper and poster ad-
vertisements, email and radio from June 2010 to March 2011. In-
clusion criteria were: a signed consent form, age 18e35 y or
60e85 y, body mass index (BMI) 18.5e30 kg/m2, good general
health, as determined by medical questionnaires and laboratory
data from screening blood and urine sample (fasting glucose,
erythrocyte sedimentation rate, full blood count, liver functiontests, renal proﬁle, dipstick urinalysis), not pregnant, lactating or
planning a pregnancy. Exclusion criteria included: allergy to the
inﬂuenza vaccine, HIV infection, diabetes requiring anymedication,
asplenia and other acquired or congenital immunodeﬁciencies, any
autoimmune disease, including connective tissue diseases, malig-
nancy, cirrhosis, connective tissue diseases, current use of immu-
nomodulating medication (including oral and inhaled steroids),
self-reported symptoms of acute or recent infection (including
use of antibiotics within last 3 months), taking lactulose or any
other treatment for constipation, alcoholism and drug misuse.
Additional exclusion criteria for older volunteers included: labo-
ratory data which were outside the normal range for this age group
and outside the ranges speciﬁed in the SENIEUR protocol [14],
Barthel Index score of <16/100, cumulative illness rating scale
(CIRS) score of >15 [15]. Additional exclusion criteria for the young
subjects included laboratory data which were outside the normal
range and inﬂuenza vaccination in the previous 12 months.
2.3. Sample size
The primary outcome of the trial was the antibody response to
vaccination, incorporating mean antibody titres, vaccine-speciﬁc Ig
subclasses and seroprotection and seroconversion. Power calcula-
tions were based on mean antibody titres. Since the inﬂuenza
vaccine is trivalent, it is unlikely that an intervention will alter the
response to all three subunits in the same way. For example, in the
study of Davidson et al. [16], there was no effect of probiotic on
mean antibody titres in response to the H1N1 subunit, whereas the
responses to both H3N2 and the B subunit were improved (72 vs 51
[SD 16.5] for H3N2 and 31 vs 25 [SD 7.1] for B subunit). Based on the
smaller effect size for the B subunit, a sample size of 26 subjects per
groupwithin each cohort was determined to be sufﬁcient for a two-
tailed signiﬁcance level of 5% and a power of 80%; this was adjusted
to 30 subjects per group to allow for dropouts. Data on the co-
primary endpoints, immunoglobulin subclasses, seroprotection
and seroconversion, is very sparse, but a sample size of 26 subjects
per group within each cohort was determined to be sufﬁcient for a
376 mg/dL difference in circulating IgG levels in response to
inﬂuenza vaccination, with an SD of 438 mg/dL, a two-tailed sig-
niﬁcance level of 5% and a power of 80% [17]. A total of 62 young
subjects and 63 older subjects entered the study and 58 young and
54 older subjects completed the study (Fig. 1). Two subjects expe-
rienced adverse effects (gastrointestinal bloating) during the study,
one on the placebo group and one in the synbiotic group; both
withdrew from the study.
2.4. Study design
Subjects consumed B. longum bv. infantis CCUG 52486
(B. longum, 109 CFU in 1 g skim milk powder/day) combined with
gluco-oligosaccharide (Gl-OS (BioEcolians, Solabia); 8 g/day)in a
double-blind, placebo controlled randomised parallel group study
design for 8 weeks. The synbiotic approach was selected because
in vitro data examining the growth and survival of this strain
indicated that it was very vulnerable compared with other strains,
but survived much better in the presence of an oligosaccharide
substrate (data not shown). When comparing a number of possible
substrates, the low water activity of Gl-OS, combined with its
ability to support the growth of the probiotic strain, made it a clear
choice for a powdered product. This prebiotic also has biﬁdogenic
effects in batch culture models [18]. The placebo used was malto-
dextrin (9 g/day); both the placebo and the pre- and pro-biotic
were sourced, packaged and blinded by BioAgro S.A. (Italy). The
powders were consumed sprinkled into water or milk or with
breakfast cereal. Microbiological safety of the product was
Fig. 1. Recruitment ﬂow diagram.
Reproduced from [13], published by Biomed Central.
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(UK) prior to commencement of the study and viability of the
probiotic strain was conﬁrmed on a weekly basis during the study.
During the three weeks prior to the study and during the inter-
vention itself, subjects were requested not to consume fermented
products such as yogurts, keﬁr etc. Subjects were randomized by a
research nurse not involved in the analysis according to gender, age
and BMI to receive the probiotic or placebo by covariate adaptive
randomization. All investigators were blinded to the treatments,
which were identical in appearance and labelled ‘A’ and ‘B’. A
research assistant not involved in the analysis generated the
random allocation sequence and a research nurse not involved in
the analysis enrolled participants and assigned the interventions.
After 4 weeks, subjects were administered with a single dose of theFig. 2. Study protocol.
Reproduced from [13], published by Biomed Central.inﬂuenza vaccine (Inﬂuvac®sub-unit2010/2011 season, Abbott Bi-
ologicals B.V., lot number 1070166) containing A/California/7/2009
(H1N1), A/Perth/16/2009 (H3N2) and the B/Brisbane/60/2008-like
strain by intra-muscular injection in the deltoid. Vaccination was
carried out by a research nurse in the presence of a qualiﬁed
clinician (MG). Details of the study schedule and samples collected
are detailed in Fig. 2. Compliance was assessed by counting
returned sachets and by copy numbers of B. longum, assessed by
qPCR. None of the subjects in the young cohort had previously
received seasonal inﬂuenza vaccination or swine ﬂu vaccination.
Three subjects in the older cohort had received swine ﬂu vaccina-
tion, and forty subjects had previously been vaccinated for seasonal
inﬂuenza, of whom thirty-seven had been vaccinated in the 2009/
2010 period.
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For serum, blood was collected into serum separator tubes and
left at room temperature for 30 min to allow coagulation. Samples
were centrifuged at 1300 g for 10 min and aliquots of serumwere
collected and stored at 80 C prior to analysis.
2.6. B cell phenotyping
B cell phenotyping was conducted by multi-parameter ﬂow
cytometry, using (FITC)-labelled anti-CD10, Pe-Cy7-labelled anti-
IgD, Apc-Cy7-labelled anti-CD19, AmCyan-labelled anti-CD27,
phycoerythrin (PE)-labelled anti-CD38, APC-labelled anti-IgA,
PerCP-labelled anti-IgM, and Paciﬁc blue-labelled anti-IgG (BD
Biosciences, Oxon, UK). The lymphocyte population was gated us-
ing forward scatter/side scatter and ﬂuorescence data for 10,000
events within the CD19þ population was collected and analysed
using FlowJo software ©Tree star. Results expressed as absolute
numbers in 1 ml of blood refer to data from ﬂow cytometric anal-
ysis of samples of whole blood stained in TruCOUNT tubes. Non-
speciﬁc staining was determined using mouse IgG1 as an isotype
negative control for PE, APC-Cy7, AmCyan, PerCP, Paciﬁc blue and
APC-labelled antibodies and IgG2a as an isotype control for FITC
and PE-Cy7-labelled antibodies. Immature B cells were identiﬁed
by the presence of both CD19-APC-Cy7 and CD10-FITC within the
lymphocyte population. Naïve B cells were identiﬁed by the pres-
ence of CD19-APC-CY7 and IgD and the absence of both CD10-FITC
and CD27-AmCyan within the lymphocyte population. Memory B
cells were identiﬁed by the presence of both CD19-APC-CY7 and
CD27-AmCyan, the absence of CD10-FITC and the absence or low
expression of CD38-PEwithin the lymphocyte population. Plasma B
cells were identiﬁed by the presence of CD19-APC-CY7 and CD27-
AmCyan, the absence of CD10-FITC and high expression of CD38-
PE within the lymphocyte population. Memory B cells were
further classiﬁed to subsets depending on their antibody expres-
sion. An IgD-PE-Cy7 vs IgM-PerCP plot was used to identify
IgMþIgDþ (non class switched; NCS) memory B cells and an IgG-
Paciﬁc Blue vs. IgA-APC plot was used to identify IgAþ and IgGþ
memory B cells. Total IgAþ and IgGþ B cells were identiﬁed using an
IgA-APC vs. IgG-Paciﬁc Blue plot.
2.7. T cell phenotyping
Peripheral blood mononuclear cells (PBMC: 1  106) were
stained with the following ﬂuorochrome-conjugated monoclonal
antibodies: (PerCP) labelled anti-CD3, (AmCyan) labelled anti-CD4,
(APC-Cy7) labelled anti-CD8, (PE-Cy7) labelled anti-CD25, (Paciﬁc
Blue) labelled anti-CD28, (APC) labelled anti-CD57, (FITC) labelled
anti-CD26, (PE) labelled anti-CD127 (Becton Dickinson, UK) and
analysed by multiparameter ﬂow cytometry (FACS Canto II, BD
Biosciences) using BD FACSDiva™ software. The lymphocyte pop-
ulation was gated using forward scatter/side scatter and ﬂuores-
cence data collected for 10,000 events within the CD3þ population.
The results are expressed as absolute numbers in 1 ml of blood,
using data from ﬂow cytometric analysis of samples of whole blood
stained in TruCOUNT tubes. Non-speciﬁc staining was determined
usingmouse IgG1 as an isotype negative control for PerCP, AmCyan,
APC-Cy7, PE-Cy7, Paciﬁc Blue, FITC and PE-labelled antibodies and
IgM as an isotype control for APC-labelled antibodies.
Total T cells were identiﬁed by the presence of CD3-PerCP and
location within the lymphocyte population in the FSC/SSC plot.
Helper and cytotoxic T cells were identiﬁed by the presence of
CD4þAmCyan and CD8þAPC-Cy7 respectively within the CD3þ T
cell population. CD25, CD26, CD28, CD57 and CD127 were used to
identify T cell subsets as shown in Supplementary Table 1.2.8. Re-stimulation of PBMC with the inﬂuenza vaccine
PBMC (106) were incubated in the presence or absence of 20 ml
inﬂuenza vaccine at 5 mg/ml for 6 days in medium containing RPMI,
10% bovine calf serum and 1% antibiotics in an air-CO2 (19:1) at-
mosphere. Cells were then stained with appropriate antibodies or
isotype controls (as above) and activation of B and T cells assessed
using (APC)-labelled anti-CD25. The lymphocyte population was
gated using forward scatter/side scatter and ﬂuorescence data for
10,000 events within the CD3þ population were collected and
analysed using BD FACSDiva™ software.
2.9. Analysis of anti-CMV IgG antibodies
Concentrations of anti-CMV IgG antibodies were analysed by
ELISA according to the manufacturer's instructions (ab108724
Anti-Cytomegalovirus (CMV) IgG Human Elisa Kit, Abcam, UK)
and read in a microplate reader (GENios) at 450 nm, with 620 nm
as a reference wavelength. CMV seropositivity was deﬁned as
antibody levels >11 AU/ml in accordance with the manufacturer's
instructions.
2.10. Statistical analysis
Data were analysed using SPSS software (version 21). Differ-
ences between groups at baseline were identiﬁed using indepen-
dent t-tests where appropriate. For the primary and continuous
secondary endpoints, a Linear Mixed Model (LMM) was imple-
mented. A ﬁrst order autoregressive covariance structure was
selected AR (1), with ﬁxed factors of time (repeated measures for 3
timepoints; baseline, 6 weeks and 8 weeks), age and treatment and
subject as a random effect. Since there were no effects of the syn-
biotic prior to vaccination (independent t tests comparing baseline
with week 4), the decision was taken to use only one ‘baseline’
timepoint in the model, and the week 4 timepoint was conse-
quently not included. Thus, the factor ‘time’ relates primarily to the
effect of vaccination. Only main effects are reported as there were
no two-way interactions between the variables. Following this
main initial analysis, the data were split by cohort (young/older)
and the analysis was repeated in the same manner to determine
time and treatment effects within each cohort. The distribution of
the data was checked using the KolmogoroveSmirnov test. If data
were not normally distributed, they were log transformed. Addi-
tional exploratory analyses examining differences between sero-
converters and non-seroconverters (at week 6) and individuals
who were CMV vs CMVþ were conducted by independent t-tests.
To account for multiple primary endpoints, two sided P values of
0.01 or less were considered statistically signiﬁcant. All missing
data were classed as missing at random and only available data
were analysed.
3. Results
3.1. Subject characteristics
The characteristics of the subjects recruited to the study are
described in Supplementary Table 2. Of the 125 volunteers who
started the trial, 112 completed (Fig. 1).
3.2. Effect of ageing and vaccination on B and T cell phenotype
Older subjects had lower numbers of all classes of memory
and plasma B cells than young subjects at baseline (Table 1).
When young and older subjects were analysed separately,
vaccination (time effect) increased numbers of memory, IgAþ
Table 1
Effects of vaccination and treatment with synbiotic on the B cell proﬁle in young and older subjects.
Absolute number  1000/ml blood
Immature Naïve
t
Memory
at
IgAþ memory
at
IgGþ memory
at
NCS memory
at
Plasma
a
Total IgAþ
a
Total IgGþ
at
Young (n ¼ 58) Placebo Baseline 7.4 ± 1.2 152.1 ± 14.3 76.0 ± 6.8 15.2 ± 1.9 12.4 ± 2.1 48.4 ± 4.2 3.4 ± 0.4 22.5 ± 2.4 18.9 ± 2.8
6 weeks 7.4 ± 0.8 155.4 ± 11.9 95.9 ± 9.4 19.0 ± 2.3 16.6 ± 3.3 60.3 ± 5.9 4.6 ± 1.1 27.7 ± 2.9 24.9 ± 4.6
8 weeks 7.5 ± 1.4 155.6 ± 15.0 85.7 ± 8.1 15.9 ± 1.8 14.3 ± 2.5 55.5 ± 5.5 2.9 ± 0.4 22.9 ± 2.2 21.4 ± 3.3
Synbiotic Baseline 7.0 ± 0.7 131.3 ± 8.7 62.8 ± 5.3 13.6 ± 1.9 11.2 ± 2.2 38.0 ± 3.0 5.5 ± 1.0 22.4 ± 2.6 18.7 ± 3.2
6 weeks 6.7 ± 0.7 138.4 ± 10.0 73.9 ± 7.6 14.3 ± 2.0 13.0 ± 2.9 46.6 ± 5.1 5.4 ± 1.6 22.4 ± 3.1 20.6 ± 3.9
8 weeks 6.5 ± 0.7 133.0 ± 10.7 67.8 ± 5.9 13.7 ± 2.0 11.0 ± 2.0 43.1 ± 3.6 4.8 ± 0.9 21.3 ± 2.8 17.7 ± 2.7
Older (n ¼ 54) Placebo Baseline 7.8 ± 0.9 122.3 ± 10.3 53.5 ± 5.0 9.5 ± 1.0 5.7 ± 1.3* 38.3 ± 3.7 2.6 ± 0.6 14.4 ± 1.4* 9.6 ± 1.7*
6 weeks 7.8 ± 1.0 122.4 ± 9.8 54.3 ± 4.9** 10.2 ± 1.2* 4.9 ± 0.6* 39.1 ± 3.8* 2.2 ± 0.4 15.2 ± 1.8** 8.7 ± 1.0*
8 weeks 6.6 ± 0.7 112.6 ± 11.0 48.6 ± 4.1** 9.2 ± 0.8* 4.3 ± 0.5** 35.1 ± 3.3* 1.9 ± 0.3 13.6 ± 1.2** 8.1 ± 0.9**
Synbiotic Baseline 7.5 ± 1.3 132.5 ± 17.0 54.5 ± 5.5 10.5 ± 1.4 6.5 ± 0.9 37.5 ± 4.4 2.6 ± 0.5 15.5 ± 1.9 11.3 ± 1.4
6 weeks 7.9 ± 1.5 132.8 ± 13.4 57.9 ± 6.1 10.9 ± 1.5 7.4 ± 1.1 39.6 ± 4.7 2.3 ± 0.3 16.2 ± 2.1 12.1 ± 1.8
8 weeks 8.5 ± 1.3 131.6 ± 16.8 56.9 ± 7.6 9.8 ± 1.5 7.7 ± 1.3 39.4 ± 6.5 2.1 ± 0.3* 14.8 ± 2.4 12.9 ± 2.1
Data are mean ± SE for n ¼ 58 young and n ¼ 54 older subjects and were analysed using a Linear Mixed Model (LMM) with ﬁxed factors of time (repeated measures), age and
treatment. There was no signiﬁcant effect of treatment for either cohort. a Denotes a signiﬁcant main effect of age (P < 0.01 at least) and t denotes a signiﬁcant main effect of
time (P < 0.01 at least) for the combined cohorts. When the effect of time was examined separately in the young and older cohorts, there were signiﬁcant effects of vaccination
on numbers of memory, IgAþ memory, IgGþ memory, NCS memory and total IgGþ B cells in the young subjects only; there were no signiﬁcant effects in the older subjects
(LMM, effect of time in young subjects P < 0.001, P < 0.01, P < 0.001, P < 0.001 and P < 0.001 respectively). *Denotes signiﬁcantly different from young subjects within the same
timepoint and treatment group at P < 0.01 and ** denotes signiﬁcantly different from young subjects within the same timepoint and treatment group at P < 0.001 (post-hoc t-
tests with Bonferroni correction).
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young subjects, but not in older subjects (LMM, effect of time in
young subjects P < 0.001, P < 0.01, P < 0.001, P < 0.001 and
P < 0.001 respectively; Table 1).
Older subjects had lower baseline numbers of CD26 helper,
CD26high cytotoxic, CD26CD28þ cytotoxic T cells and CD28CD57
cytotoxic T cells, but higher numbers of CD26þ helper T cells (Th1)
and senescent CD28CD57þ helper and cytotoxic T cells than young
subjects (Table 2), demonstrating clear evidence of immunose-
nescence in the older subjects. There was no signiﬁcant effect of
vaccination (time) on T cell subsets (Table 2).3.3. B and T cell phenotype inﬂuences seroconversion
Seroconverters to the H1N1 subunit in the older cohort had
signiﬁcantly higher post vaccination numbers of plasma B cells
(Fig. 3; independent t-test). For the H3N2 and Brisbane subunits,
there were trends for associations with IgGþ memory and total B
cells, but these were not statistically signiﬁcant (data not shown).Table 2
Effects of vaccination and treatment with synbiotic on the T cell proﬁle in young and old
Absolute number  1000/ml blood
CD26þ
helper
a
CD26
helper
CD26high
cytotoxic
a
Young
(n ¼ 58)
Placebo Baseline 308 ± 29 410 ± 20 28 ± 3
6 weeks 332 ± 30 454 ± 24 30 ± 4
8 weeks 322 ± 26 433 ± 25 27 ± 3
Synbiotic Baseline 341 ± 30 445 ± 36 30 ± 4
6 weeks 372 ± 31 467 ± 32 30 ± 5
8 weeks 316 ± 30 394 ± 31 25 ± 4
Older
(n ¼ 54)
Placebo Baseline 435 ± 33* 339 ± 24 15 ± 2**
6 weeks 388 ± 33 315 ± 26** 13 ± 2**
8 weeks 415 ± 35 316 ± 26* 14 ± 2*
Synbiotic Baseline 408 ± 35 369 ± 35 14 ± 2*
6 weeks 446 ± 33 386 ± 29 14 ± 3*
8 weeks 412 ± 34 361 ± 31 14 ± 4*
Data are mean ± SE for n ¼ 58 young and n ¼ 54 older subjects and were analysed using a
treatment. There were no signiﬁcant effects of either time or treatment for either cohort
different from young subjects within the same timepoint and treatment group at P < 0.01
and treatment group at P < 0.001 (post-hoc t-tests with Bonferroni correction).Seroconversion was less consistently associated with T cell
phenotype. We previously reported that high numbers of senescent
(CD28CD57þ) T cells were associatedwith failure to seroconvert to
the inﬂuenza vaccine [13]. Further analysis of T cell phenotype
demonstrated that seroconverters to all 3 subunits combined had
signiﬁcantly higher post vaccination numbers of Tregs (P < 0.001;
combined cohorts, independent t-test; Fig. 4), and this was
particularly signiﬁcant for the Brisbane strain (P < 0.01, combined
cohorts, independent t-test). Numbers of non-senescent
CD26CD28þ cytotoxic T cells 2 weeks post vaccination were also
signiﬁcantly higher in responders to Brisbane (P < 0.001, combined
cohorts, independent t-test) (data not shown).
3.4. Effect of the synbiotic on B and T cell phenotype
Intervention with the synbiotic did not alter B or T cell pheno-
type in either young or older subjects prior to vaccination (data not
shown), and for this reason, the Linear Mixed Model analysis was
applied to data collected at baseline, 6 weeks and 8 weeks only.
Following vaccination, numbers of IgGþ memory B cells tended toer subjects.
CD26int
cytotoxic
a
CD26CD28þ
cytotoxic
a
CD26CD28
cytotoxic
CD28CD57þ
cytotoxic
a
CD28CD57
cytotoxic
a
103 ± 10 225 ± 21 103 ± 11 65 ± 9 47 ± 5
124 ± 16 248 ± 23 112 ± 10 61 ± 8 54 ± 4
102 ± 9 240 ± 24 110 ± 12 69 ± 9 54 ± 6
111 ± 10 233 ± 21 118 ± 11 73 ± 10 55 ± 6
110 ± 11 224 ± 18 120 ± 14 79 ± 14 51 ± 5
104 ± 9 208 ± 17 121 ± 13 78 ± 12 53 ± 5
77 ± 7 108 ± 15** 136 ± 26 120 ± 24 25 ± 3**
75 ± 8 105 ± 15** 131 ± 23 117 ± 22 23 ± 3**
74 ± 8 94 ± 13** 142 ± 28 127 ± 26 23 ± 4**
84 ± 12 112 ± 15** 212 ± 37 181 ± 32* 41 ± 9
85 ± 15 99 ± 10** 194 ± 46 169 ± 39 35 ± 10*
89 ± 13 112 ± 17** 219 ± 37 186 ± 30* 45 ± 10
Linear Mixed Model (LMM) with ﬁxed factors of time (repeated measures), age and
. a Denotes a signiﬁcant main effect of age (P < 0.01 at least). *Denotes signiﬁcantly
and ** denotes signiﬁcantly different from young subjects within the same timepoint
Fig. 4. Higher numbers of regulatory T cells are associated with seroconversion to all
subunits combined in the combined cohort. Data are mean ± SE for n ¼ 58 young and
n ¼ 54 older subjects. *Denotes signiﬁcantly different from non-seroconverters within
the same age group (P < 0.01, independent t-test).
Fig. 5. Effects of vaccination and synbiotic on numbers of IgGþmemory and IgGþ total
B cells in older subjects. Data are mean ± SE for n ¼ 54 older subjects. Numbers of IgGþ
memory and IgGþ total B cells tended to increase in the older subjects receiving the
synbiotic (-), but not in those receiving the placebo (▫) (LMM, effect of treatment,
older cohort, P ¼ 0.068 and P ¼ 0.09 respectively).Fig. 3. Higher numbers of circulating plasma B cells are associated with seroconver-
sion to H1N1 in the older cohort. Data are mean ± SE for n ¼ 58 young and n ¼ 54
older subjects. *Signiﬁcantly different from non-seroconverters within the same age
group (P < 0.01, independent t-test).
S. Enani et al. / Clinical Nutrition 37 (2018) 443e451448increase in the older subjects receiving the synbiotic, but not in
those receiving the placebo (Fig. 5). This was not the case in the
young subjects, where there was no effect of the symbiotic (data
not shown). Numbers of CD25high total and helper T cells increased
more in the older subjects who received the synbiotic than those
receiving placebo (LMM, effect of treatment in the older cohort,
P < 0.01; data not shown). As reported previously, older subjects
who were randomized to the synbiotic had a signiﬁcantly higher
baseline number of senescent (CD28CD57þ) helper T cells and a
trend towards higher baseline numbers of senescent
(CD28CD57þ) cytotoxic T cells compared with age-matched sub-
jects who were randomized to the placebo, and this was associated
with failure to seroconvert to the Brisbane subunit of the vaccine[13]. However, there were no other phenotypic differences in the B
or T cell populations in the randomized groups at baseline.
3.5. Responsiveness of B cells to in vitro re-stimulation with ﬂu
vaccine prior to vaccination is affected by ageing
As expected, vaccination increased B cell responsiveness to
in vitro exposure to the vaccine. This was reﬂected in the higher
proportion of activated (CD25þ) cells within the naïve, memory
and plasma B cell compartments, both in the combined and
separate cohorts (Table 3). Activation of memory B cells (% CD25þ)
in response to in vitro re-stimulationwith the vaccine was greater
in young subjects than in older subjects (LMM, effect of age,
p < 0.001; Table 3), and there was a similar trend for plasma B
cells (P < 0.05).
Seroconverters to the H3N2 and Brisbane subunits demon-
strated greater responsiveness of memory B cells (% CD25þ) to
in vitro re-stimulation with the inﬂuenza vaccine than non-
converters (P < 0.01 and P < 0.01 respectively for combined co-
horts, data not shown). Responsiveness of plasma B cells to in vitro
re-stimulation tended to be greater in seroconverters to Brisbane
comparedwith non-seroconverters (P < 0.02 for combined cohorts;
data not shown). These differences were not maintained when the
young and older subjects were analysed separately.
3.6. Responsiveness of T cells to in vitro re-stimulation with ﬂu
vaccine
As expected, vaccination increased T cell responsiveness to
in vitro exposure to the vaccine, but there was no signiﬁcant effect
of age. This increased responsiveness was reﬂected in the higher
proportion of activated (CD25þ) cells and of mean ﬂuorescence
intensity within the CD4þ and CD8þ T cell compartments when
young and older subjects were combined (LMM, effect of time,
combined cohorts, P < 0.001), and within the young cohort (LMM,
effect of time P < 0.001 at least, young cohort; Table 4), but not the
older cohort. Although this suggests a greater responsiveness to the
vaccine of T cells from young subjects, there was no signiﬁcant ef-
fect of age according to the LMM. Furthermore, unlike B cells, there
was no clear relationship between the responsiveness of T cells to
re-stimulationwith inﬂuenza vaccine and the antibody response to
the vaccine or seroconversion (data not shown).
Table 3
Responsiveness of B cells to in vitro re-stimulation with ﬂu vaccine.
CD25 (%)
Naïve
t
CD25 (%)
Memory
at
CD25 (%)
Plasma
t
CD25 MFI
Naïve
at
CD25 MFI
Memory
t
CD25 MFI
Plasma
t
Young (n ¼ 58) Placebo Baseline 6.5 ± 0.7 15.5 ± 1.6 14.4 ± 2.2 171 ± 21 363 ± 83 1375 ± 347
6 weeks 9.5 ± 1.0 22.5 ± 2.3 16.3 ± 2.2 219 ± 24 550 ± 111 1618 ± 499
8 weeks 9.8 ± 1.2 23.6 ± 2.2 17.0 ± 1.8 231 ± 26 484 ± 90 1704 ± 490
Synbiotic Baseline 8.0 ± 0.8 14.2 ± 1.6 12.5 ± 1.4 204 ± 21 160 ± 56 1554 ± 347
6 weeks 12.0 ± 1.0^ 22.6 ± 1.9^ 20.5 ± 2.4 299 ± 26 405 ± 70 2339 ± 678
8 weeks 10.0 ± 0.9 18.2 ± 1.9 18.3 ± 2.9 212 ± 24 261 ± 71 1447 ± 748
Older (n ¼ 54) Placebo Baseline 9.4 ± 1.8 8.9 ± 2.5 5.0 ± 1.9* 502 ± 129 674 ± 338 637 ± 664
6 weeks 12.7 ± 1.9 13.2 ± 2.5* 12.7 ± 2.8 629 ± 137 1401 ± 672 3319 ± 965
8 weeks 13.9 ± 2.2 14.0 ± 2.8* 18.3 ± 3.3^ 665 ± 152 1377 ± 560 2953 ± 1015
Synbiotic Baseline 6.1 ± 0.9 6.8 ± 2.6 7.1 ± 4.5 235 ± 50 126 ± 280 907 ± 367
6 weeks 8.8 ± 1.2 11.6 ± 2.3* 13.6 ± 3.5 315 ± 61 708 ± 228 2083 ± 760
8 weeks 9.2 ± 1.2 13.5 ± 2.2 13.1 ± 4.0 275 ± 41 721 ± 157 1965 ± 483
Data are mean ± SE for n ¼ 58 young and n ¼ 54 older subjects and were analysed using a Linear Mixed Model (LMM) with ﬁxed factors of time (repeated measures),
age and treatment. There was no signiﬁcant effect of treatment for either cohort. a Denotes a signiﬁcant main effect of age (P < 0.01 at least) and t denotes a signiﬁcant
main effect of time (P < 0.01 at least) for the combined cohorts. When the effect of time was examined separately in the young and older cohorts, there were sig-
niﬁcant effects of vaccination in all B cell subsets (P < 0.01 at least). Activation of memory B cells (% CD25þ) in response to in vitro re-stimulation with the vaccine was
greater in young subjects than in older subjects (LMM, effect of age, P < 0.001). *Denotes signiﬁcantly different from young subjects within the same timepoint and
treatment group at P < 0.01 and ^denotes signiﬁcantly different from baseline within the same age and treatment group at P < 0.01 (post-hoc t-tests with Bonferroni
correction).
Table 4
Responsiveness of T cells to in vitro re-stimulation with ﬂu vaccine.
CD25 (%)
Total T cells
t
CD25 (%)
CD4þ T cells
t
CD25 (%)
CD8þ T cells
t
CD25 MFI
Total T cells
t
CD25 MFI
CD4þ T cells
t
CD25 MFI
CD8þ T cells
t
Young (n ¼ 58) Placebo Baseline 9.3 ± 0.6 9.2 ± 0.6 6.9 ± 0.6 329 ± 35 389 ± 43 99 ± 19
6 weeks 11.8 ± 1.0 11.2 ± 0.9 9.6 ± 1.0 392 ± 57 447 ± 63 171 ± 23
8 weeks 12.2 ± 1.3 11.3 ± 1.2 10.6 ± 1.5 386 ± 58 420 ± 67 186 ± 27
Synbiotic Baseline 10.1 ± 0.6 9.5 ± 0.5 8.6 ± 0.7 332 ± 44 353 ± 38 154 ± 30
6 weeks 14.0 ± 0.9 12.9 ± 0.9 12.6 ± 0.8 476 ± 58 533 ± 64 225 ± 28
8 weeks 11.3 ± 0.8 11.1 ± 1.0 9.8 ± 0.7 379 ± 54 427 ± 55 159 ± 22
Older (n ¼ 54) Placebo Baseline 8.6 ± 1.3 7.2 ± 1.6 11.7 ± 2.3 397 ± 77 307 ± 136 621 ± 210
6 weeks 12.6 ± 1.8 11.0 ± 1.9 13.9 ± 2.2 725 ± 129 537 ± 130 852 ± 254
8 weeks 13.0 ± 1.9 11.7 ± 2.1 14.1 ± 2.4 710 ± 156 577 ± 188 782 ± 244
Synbiotic Baseline 7.9 ± 1.5 7.9 ± 1.6 7.2 ± 1.9 324 ± 104 427 ± 180 267 ± 113
6 weeks 10.4 ± 2.0 10.6 ± 2.2 8.5 ± 2.1 483 ± 98 621 ± 174 252 ± 91
8 weeks 11.9 ± 2.4 12.0 ± 2.6 10.6 ± 2.6 527 ± 121 798 ± 286 301 ± 77
Data are mean ± SE for n ¼ 58 young and n ¼ 54 older subjects and were analysed using a Linear Mixed Model (LMM) with ﬁxed factors of time (repeated measures), age and
treatment. There was no signiﬁcant effect of either age or treatment for either cohort. t Denotes a signiﬁcant main effect of time (P < 0.01 at least) for the combined cohorts.
When the effect of time was examined separately in the young cohort, there were signiﬁcant effects of vaccination in all T cell subsets (P < 0.01 at least), but this was not the
case in the older cohort.
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cytotoxic T cells to in vitro re-stimulation with the inﬂuenza vaccine
49% of young and 53% of older subjects were seropositive
for CMV, with no signiﬁcant difference between age groups.
In young subjects, CMV seropositivity had no inﬂuence on
responsiveness of either naïve B cells or cytotoxic T cells to
in vitro re-stimulation with the vaccine (Fig. 6A). However, in
older subjects, CMV seropositivity was associated with signiﬁ-
cantly lower responsiveness to the vaccine in these subsets
(Fig. 6B). Other B and T cell subsets were not inﬂuenced by CMV
seropositivity.
3.8. Effect of the synbiotic on responsiveness of B and T cells to
in vitro re-stimulation with inﬂuenza vaccine
There were no signiﬁcant effects of the synbiotic on the
responsiveness of either B cells or T cells to re-stimulation with
inﬂuenza vaccine, which suggests that overall, there was no effect
of treatment on antigen recall (data not shown).4. Discussion
Inﬂuenza vaccination increased numbers of key B cell subsets in
young subjects, but failed to do so in older subjects and this had a
signiﬁcant impact on seroconversion. B and T cell subsets demon-
strated a strong response to the antigen-speciﬁc recall challenge for
both young and older subjects, and although not inﬂuenced by
ageing, responsiveness to the recall challenge was associated with
seroconversion. In older subjects, CMV seropositivity was associ-
ated with a signiﬁcantly lower recall response to the vaccine.
Overall, there was little evidence of any effect of the synbiotic on
the responsiveness of B or T cells to re-stimulation with inﬂuenza
vaccine.
This study conﬁrmed some of the well-documented age-related
alterations in B and T cell phenotype, including restricted B cell di-
versity, reduced numbers of memory and plasma B cells and accu-
mulation of terminally differentiated senescent CD28CD57þ helper
and cytotoxic T cells. In a previous paper, we demonstrated that
these age-related alterations in the T cell proﬁle were related to an
impaired antibody response to the Brisbane subunit [13]. In the
(A)
(B)
*
**
Fig. 6. Effect of CMV seropositivity on responsiveness of B and T cells to in vitro re-
stimulation with the inﬂuenza vaccine. Data are mean ± SE for n ¼ 45 young (A)
and n ¼ 44 older (B) subjects. *Denotes signiﬁcantly different from CMV subjects
(P < 0.01, independent t-test).
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memory B cells following inﬂuenza vaccination increased to a
signiﬁcantly greater degree in the young subjects compared with
the older subjects. This was correlated with the magnitude of the
serological antibody response, which provides novel insight into the
impact of ageing on the relationship between expanding B cell
subsets and seroconversion following inﬂuenza vaccination [19].
Class-switching of memory and plasma B cells to IgAþ and IgGþ cells
declines during ageing, resulting in a weaker humoral immune
response and impaired protection against pathogens [20]. The cur-
rent study demonstrated that numbers of isotype class-switched
memory and total IgAþ and IgGþ B cells were signiﬁcantly lower
in the older subjects compared with the young subjects at baseline.
Nevertheless, older subjects who seroconverted to H3N2 had
greater numbers of IgAþ and IgGþ memory and total IgGþ B cells
prior to vaccination. Similarly, seroconverters to the Brisbane sub-
unit had greater numbers of total IgAþ B cells prior to vaccination.
This is consistent with the suggestion of an association between the
proportion of circulating class-switched B cells prior to inﬂuenza
vaccination and the antibody response after vaccination [21].
In the current study, although seroconversion was less consis-
tently associated with T cell phenotype, high levels of CD26þ Th1memory cells prior to vaccination were related to an impaired
antibody response to Brisbane, in addition to the CD28CD57þ
senescent T cells reported in our previous paper [13]. There was an
increase in CD4þCD25high T cells and Tregs following vaccination in
young subjects, which is consistent with a previous study [22].
Seroconverters to all 3 subunits combined had signiﬁcantly higher
post vaccination numbers of Tregs, and this was particularly sig-
niﬁcant for the Brisbane strain. The role of Tregs in humoral
immunity and the antibody response to vaccination is unclear,
although some studies report an inverse relationship between
Tregs and the antibody response to vaccination [23]. It has been
suggested that increases in CD4þCD25high T cells and Tregs after
inﬂuenza vaccination increase levels of IL-10 and are negatively
correlated with TGF-b, which results in suppression of the antibody
response [22].
In vitro re-stimulation of B cells with the inﬂuenza vaccine re-
sults in induction of CD25 [24]. Morphologically, CD25þ B cells are
larger in size and more granulated than CD25 B cells, they
demonstrate greater expression of the IL-2 receptor and of the co-
stimulatory molecules, CD80 and CD27, and have higher frequency
and density of expression of IgA and IgG, but lower expression of
MHC class II [25]. Functionally, CD25þ B cells have lower production
of Ig than CD25- B cells, even though they have greater surface
expression of Ig [25]. Despite lower expression of MHC class II,
CD25þ B cells have greater antigen presentation activity than
CD25 B cells, perhaps due to greater expression of CD80 and CD27.
The greater antigen presentation activity contributes to greater
in vitro stimulation of T helper cell proliferation compared to CD25
B cells. Antibody neutralization of CD25 removes this effect,
demonstrating the importance of this surface molecule in B cell
activation and function [25]. Vaccination increased the respon-
siveness of B cells to an antigen-speciﬁc recall challenge with the
vaccine, evidenced by an increase in the percentage of CD25þ
memory and plasma B cells, reﬂecting a strong secondary response
of B cells to the vaccine. The responsiveness of B cells from young
subjects to in vitro re-stimulationwith the vaccine was signiﬁcantly
greater than that of older subjects. Memory and plasma B cells from
seroconverters were more responsive to in vitro stimulation with
the vaccine than non-converters, both before and after vaccination,
for all three subunits combined and for the H3N2 and Brisbane
subunits, but not for H1N1. Furthermore, impaired responsiveness
in older subjects was associated with low antibody production in
response to vaccination, which suggests that in vitro responsiveness
of B cells to the inﬂuenza vaccine may be a useful functional marker
of the immune response to vaccination. Vaccination also resulted in
greater T cell responsiveness to an antigen-speciﬁc recall challenge,
but unlike B cells, there was little or no inﬂuence of age. Further-
more, there was no clear relationship between the responsiveness
of T cells to antigen recall and the antibody response to the vaccine
or seroconversion. Interestingly, CMV seropositivity was associated
with signiﬁcantly lower responsiveness to the vaccine in older
subjects only; this is relevant because latent infectionwith CMV has
been demonstrated to result in a poor response to infection and
vaccination [26].
We previously demonstrated that intervention with a novel
synbiotic, B. longumþ Gl-OS failed to reverse the impairment in the
antibody response to inﬂuenza vaccination in older subjects.
However, further immunological characterization revealed a
greater degree of immunosenescence at baseline in older subjects
randomized to the synbiotic, which could have explained the
particularly poor response of these subjects to the vaccination. This
highlighted the fact that interpretation of interventions examining
the response to vaccination in older people may be highly depen-
dent on their baseline immunological phenotype. In the current
study, intervention with the synbiotic did not alter B or T cell
S. Enani et al. / Clinical Nutrition 37 (2018) 443e451 451phenotype in either young or older subjects prior to vaccination,
but following vaccination, numbers of IgGþmemory B cells tended
to increase more in the older subjects receiving the synbiotic than
those receiving the placebo and numbers of CD25high total and
helper T cells increasedmore in the older subjects who received the
synbiotic than those receiving placebo. Thus, the greater degree of
immunosenescence in the synbiotic group at baseline appears to
have had little impact on numbers of memory B cells and helper T
cells following vaccination. Overall, therewere no other phenotypic
difference in the B and Tcell populations. Therewas also no effect of
the synbiotic on the antigen-speciﬁc recall challenge, but this may
well be due to the greater degree of immunosenescence in the older
subjects randomized to the synbiotic masking any beneﬁcial ef-
fects. Beneﬁcial effects of probiotics on immune function have been
reported in some, but not all, human studies [27] and some studies
report decreased incidence of and/or duration of ﬂu by probiotics
after inﬂuenza vaccination [17,28]. However, intervention studies
evaluating the impact of probiotics on the immune response to
vaccination are limited and report inconsistent results regarding
vaccine-speciﬁc antibody production, with the majority being
conducted in adults and only a few in elderly subjects [10]. Most
of these studies simply report antibody titres, with no further
immunological exploration [10]. This paper demonstrates that
aspects of the humoral response to vaccination are markedly
inﬂuenced by ageing, but resistant tomanipulation by pre- and pro-
biotics.
5. Conclusion
In conclusion, while vaccination altered the B and T cell proﬁle
differentially in young and older subjects, antigen-speciﬁc B and T
cell activation following an in vitro recall challenge with the inﬂu-
enza vaccine was not altered by a synbiotic in either young or older
subjects.
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